Previous studies have demonstrated that the selective cyclooxygenase-2 (COX-2) inhibitor celecoxib shows efficacy against multiple cancers, including hepatocellular carcinoma. However, whether celecoxib is effective in alleviating steatosis during hepatocarcinogenesis is unknown. In a rapid hepatocellular carcinoma 
| INTRODUCTION
Hepatocellular carcinoma (HCC) is one of the most common malignancies, and its incidence is expected to rise globally in the future years. 1 The therapeutic strategies for HCC are still limited in advanced liver cancer, which results in a high mortality rate in terminal HCC patients (HCCs). Epidemiological observations suggested that hepatitis virus (B, HBV; C, HCV) infection, nonalcoholic steatohepatitis (NASH) and nonalcoholic fatty liver disease (NAFLD) are all risk factors that increase the incidence of HCC. 2 Unfortunately, some HCCs are not suitable for tumor removal, due to tumor deterioration or severe liver dysfunction from steatosis or inflammatory infiltration. 3 Therefore, discovering potential agents against steatosis and inflammation in HCC development may be beneficial for HCC treatment.
There have been various molecular discoveries regarding the interactions between chronic inflammation and tumorigenesis in recent years. Activated nuclear factor κB (NF-κB) is a trigger for inducing chronic inflammatory diseases and promotes inflammationassociated cancer cell survival. 4 Cyclooxygenase-2 (COX-2), an inducible catalyzing enzyme for prostaglandin E2 (PGE2) synthesis, has become a potential target for the prevention of colorectal carcinoma. 5, 6 Nonsteroidal anti-inflammatory drugs (NSAIDs), such as selective COX-2 inhibitors, are effective at inhibiting COX-2 activity, and therefore these agents are chemo-preventive in clinical and animal trials of intestinal tumorigenesis. 7, 8 In fact, the COX-2-dependent carcinogenic effect also functions to promote cell proliferation, reduce apoptosis and accelerate angiogenesis in some experimental HCC models. 9, 10 However, unlike the expression pattern of COX-2 in colon cancer, elevated expression of COX-2 in well-differentiated HCCs and reduction of COX-2 expression in poorly differentiated HCC samples suggests that COX-2 might play a key role in the early stages of hepatocarcinogenesis, rather than in the advanced stages. 11 Furthermore, lipid metabolic disturbances are considered a hallmark of HCCs.
More importantly, hepatic lipid accumulation is more abundant in the development of HCC than that in its advanced stages. 12 Although both steatosis and hepatitis are accelerators of early HCC development, an underlying correlation between steatosis and inflammation during HCC formation is still rare. Hence, whether selective COX-2 inhibitors could alleviate excessive lipid accumulation in hepatocarcinogenesis needs to be clarified.
The V-akt murine thymoma viral oncogene homolog (AKT)/mTOR cascade is commonly activated in human hepatocarcinogenesis. 13, 14 Phosphorylated Akt triggers its downstream effector, mTOR complex 1 (mTORC1), that further controls protein translation and cell metabolism by enhancing the phosphorylation of eukaryotic initiation factor 4E-binding protein 1 (4E-BP1) and ribosomal protein S6 kinase (also known as p70S6K). 13 
| Hydrodynamic injection and animal administration
Wild-type FVB/N mice were purchased from Charles River (Beijing, China). The hydrodynamic transfection was performed as previously described. 16 Two millimeter of normal saline solution containing 20 µg pT3-EF1α-HA-myr-AKT and 20 µg pT3-EF1α-V5-c-Met along with 
| Cell viability and LPS stimulation
Cell viability was evaluated using CCK-8 assays with WST-8 as described in our previous study. 19 To enhance inflammatory responses and activate COX-2-induced PEG2 synthesis in HCC cells in vitro, cells were seeded in plates and were stimulated with LPS (100 µg/L) in the presence or absence of celecoxib (10-50 µM) for 24 h. Then, cells were further tested for viability, and protein immunoblotting assays were performed.
2.6 | Western blotting (WB), ELISA, hematoxylin-eosin (H&E) staining and immunohistochemistry (IHC)
The protein preparation and immunoblotting procedures for cells and hepatic tissues were performed as previously described. 19 The specific primary antibodies used in immunoblotting are listed in Supplementary   Table S1 (See Supplementary Information).
For H&E staining, sections from paraffin-embedded liver tissues were dewaxed in xylene and rehydrated by ethanol at decreasing concentrations. The sections were then stained with H&E and dehydrated using ethanol and xylene.
For immunohistochemical staining, deparaffinized liver tissue sections were incubated with 3% H 2 O 2 and microwaved for background removal and antigen retrieval, respectively. Specific primary antibodies used in immunohistochemistry were listed in Supplementary Table S1 . Antibody incubation and visualization of immunoreactivity were conducted as previously described. 20 
| Statistical analysis
Data analysis was performed with Prism 6 (GraphPad). Data are shown as means ± S.D. from at least three independent experiments.
Comparisons between two groups and among three or more groups were performed using a two-tailed unpaired t-test or ANOVA, respectively. P values <0.05 were considered statistically significant. 
| DISCUSSION
A continuous inflammatory response can increase the risk of tumorigenesis. 21 Reactive oxygen species produced during chronic inflammation transcriptionally activates proto-oncogenes and triggers cancer-related signaling pathways. Additionally, DNA damage, abnormal cellular growth, alteration of the extracellular microenvironment, arrest of apoptosis, infiltrative angiogenesis and tumor metastasis are frequent events in hyperactive inflammatory responses, which could be partly attributed to the abundant expression of inflammatory enzymes such as COX-2. 22 Rapidly inducible COX-2 is released in response to multiple cellular stimuli and functions as a catalyzer to convert arachidonic acid to prostaglandins, which subsequently mediate inflammation, angiogenesis, and immunomodulation. Initially, the tumor-promoting action of COX-2 was credibly identified in colorectal carcinogenesis. 23 Both epidemiological studies and preclinical investigations of colon carcinogenesis indicated that, due to a significant and persistent accumulation of COX-2 in more than 70% of colon cancer patients, NSAID therapy such as aspirin and specific COX-2 inhibitors might be a potential strategy for prevention and treatment of colorectal cancer. 7, 24 Nevertheless, the enzymatic activity of COX-2 is not always positively correlated with the developmental course of other neoplasms. In the initiation and development of HCC, the pattern of COX-2 expression is much more intricate than that in a COX-2-associated colorectal carcinoma. 25 There is mounting pathological evidence that COX-2 might be pivotal in the early stages of hepatocarcinogenesis and could be partially attributable to the increase of microvessel density (MVD) and the induction of cell proliferation. 26 However, whether COX-2 functionally manipulates lipid metabolism in ) and FASN were evaluated using a Western blot assay (C). Histograms in (D) represent the intensity of the bands of immunoblotting in (C) quantitated by densitometry. The housekeeping gene β-actin was used as an internal control. Quantitative data are the mean ± S.D. of the density values from the Western blot assay, n = 3. *P < 0.05, **P < 0.01; ***P < 0.001 versus the MOCK group hepatocarcinogenesis remains poorly defined. In the present study, we found that COX-2 is upregulated (Figure 1 As previously mentioned, Lu et al noted no difference in phosphorAkt (Thr308) expression in the livers of celecoxib-treated rats compared with high-fat-fed rats, whereas the expression of phosphor-Akt (Ser473) was higher in the liver tissues of celecoxib-treated rats than in the model control group. Some evidence indicated that the AKT/mTOR and mitogen-activated protein kinase (MAPK) signaling cascades were responsible for regulating de novo lipogenesis. 31, 32 Moreover, an AKT/mTORC1/FASN axis, but not the MAPK cascade, was a key modulator to drive the process of lipid biosynthesis in HCC. 16 In the present study, the celecoxib-induced reduction of phosphor-Akt (Thr308) expression is in accordance with previous studies in some established human HCC cell lines and rat C611B cholangiocarcinoma cells. 33, 34 Different from the findings focusing on the apoptotic potential of celecoxib in the in vitro studies, the present work indicated that celecoxib weakened the overexpression of activated AKT at the Thr308 residue but had no effect on phosphorylation at the Ser473 residue, which resulted in reduction of the protein expression of FASN and lipid biosynthesis in AKT/c-Met HCC mice. In fact, phosphoinositide-dependent protein kinase 1 (PDK1) phosphorylates Akt at the Thr308 residue, resulting in necessary activation of Akt function. 35 In addition, phosphorylation of Akt at the Ser473 residue by mTORC2 also triggered Akt activity. Nevertheless, phosphor-Akt (Ser473) is not required for Akt to activate mTORC1. 36 In the aforementioned literature, 33 celecoxib suppressed Akt phosphorylation at Thr308 by inhibition of PDK1 and PTEN phosphorylation in HCC cells, which closely resembles those effects found in human cholangiocarcinoma cell lines. 37 Thus, it could explain that celecoxib reduces the phosphor-Akt (Thr308) expression during AKT/c-Met-driven hepatocarcinogenesis, which is probably involved in dephosphorylation of PDK1.
De novo lipogenesis is involved in tumorigenesis. Inhibition of the key lipogenic enzymes can both strongly obstruct the in vitro growth of numerous tumor types and to delay oncogenesis in vivo. 32 Altogether, this study broadens the hypothesis that inhibition of the inflammatory response is efficient in delaying hepatocarcinogenesis by attenuating hepatocellular steatosis. Because lipogenesis and steatosis are common in some predisposing conditions for human HCC 43, 44 or experimental preneoplastic mouse liver lesions, 45 drugs or other potential natural supplements (such as celastrol), targeting COX-2 activity may be beneficial both as a chemopreventive and therapeutic agent for HCC. Undeniably, high-efficiency COX-2 inhibitors are commercially available and still have some adverse effects. 46 Therefore, further preclinical studies and clinical observations using these chemicals to alleviate "inflammation-lipogenesis" crosstalk in HCC should be performed.
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